MedTrace Logo

Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study

NCT01220817 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2012-04-06

No results posted yet for this study

Summary

When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer. Further, the investigators believe that POMx will be shown to be safe and well tolerated.

Conditions

  • Recurrent Prostate Cancer

Interventions

DRUG

3 POMx capsules

3 POMx capsules daily

DRUG

1 POMx capsule

1 POMx capsule daily

Sponsors & Collaborators

  • POM Wonderful LLC

    lead INDUSTRY

Principal Investigators

  • Michael Carducci, MD · Sidney Kimmel Cancer Center, Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01220817 on ClinicalTrials.gov